Literature DB >> 21728750

Late nodal metastasis of T2 oral cancer can be reduced by a combination of preoperative ultrasonographic examination and frozen section biopsy during supraomohyoid neck dissection.

Koutetsu Lee1, Shuji Nishikawa, Katsuhiro Yoshimura, Ryo Kawata.   

Abstract

CONCLUSION: The occult metastasis rate for T2 oral cancer can be reduced by ultrasonography (US). Also, the late metastasis rate is considered to be reduced by combining US with frozen section biopsy (FSB) during supraomohyoid neck dissection (SOHND).
OBJECTIVES: Early oral cancer has been reported to show occult metastases in 15-53% of patients, but the criteria or methods for the diagnosis of cervical lymph node metastasis are unclear in many studies, and there is no clear definition of occult metastasis. In patients with T2 oral cancer, the diagnosis of lymph node metastasis by US and its pathological diagnosis (pN) after neck dissection were compared to evaluate the usefulness and limitations of US, occult metastasis rate, significance of SOHND as preventive neck dissection, and use of FSB.
METHODS: A total of 73 patients with T2 oral cancer were investigated retrospectively. Modified radical neck dissection (MRND) was performed in N+ patients, and SOHND was carried out in N0 patients. FSB was performed in all patients undergoing SOHND. US and pN diagnoses were compared.
RESULTS: The occult metastasis rate was 18% when occult metastases were limited to those detected by SOHND and 22% when late nodal recurrences were also included.

Entities:  

Mesh:

Year:  2011        PMID: 21728750     DOI: 10.3109/00016489.2011.598553

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  Patterns of lymph node metastasis and the management of neck dissection for parotid carcinomas: a single-institute experience.

Authors:  Tsuyoshi Jinnin; Ryo Kawata; Masaaki Higashino; Shuji Nishikawa; Tetsuya Terada; Shin-Ichi Haginomori
Journal:  Int J Clin Oncol       Date:  2019-02-09       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.